HDAC9 and neoplasm: Studies have demonstrated that HDAC inhibitors upregulate the NKG2D ligands on tumor cells, thereby sensitizing tumor cells to cytotoxicity mediated by γδ T cells in bladder cancer as well as NK cells in other malignancies such as osteosarcoma, pancreatic cancer, and multiple myeloma (32, 58–60).